Tiantan biology related company

Zhongsheng Group is the controlling shareholder of Beijing Institute of Biological Products and the ultimate controller of Tiantan Biology. After the free transfer, Tiantan Bio was upgraded from Sun Company of Zhongsheng Group to a subsidiary. At this point, the actual controller of the company, China Biotechnology Group Company, holds 65,438+0,836,5438+0.5 million shares of Tiantan Bio, accounting for 56.27% of the company's total share capital and becoming the largest shareholder of Tiantan Bio.

Tiantan Bio, a listed company, has repeatedly announced that China Biotechnology Group Company has set up an overall listing working group, and will gradually integrate the internal business of the group system and optimize resource allocation through private placement, asset acquisition and merger in the near future. The overall plan is to inject its six biological research institutes into Tiantan biology and set up a national vaccine center for microgroove biology. Beijing Institute of Biological Products, founded in 19 19, is the earliest unit engaged in microbiology, immunology research and production of epidemic prevention products in China. Originally under the direct administration of the Ministry of Health, it now covers an area of 560,000 square meters with a building area of 1 1 10,000 square meters. Employees 1473, scientific and technical personnel 6 12, accounting for 42% of the total number of employees. Among them, there are 88 senior technicians and 0/70 intermediate technicians. This institute is not only the first unit in China to carry out important research projects and successfully develop and popularize important epidemic prevention products, but also the first unit in China to study antibiotics. The Institute produces various epidemic prevention products, blood products and diagnostic products, which have made outstanding and important contributions to preventing, controlling and even reducing infectious diseases, improving people's health level and prolonging people's life span.

The late Professor Tang successfully isolated Chlamydia trachomatis for the first time in the world and won the gold medal of "International Trachoma Organization". China's first successfully developed blood-borne hepatitis B vaccine won the first prize of National Science and Technology Progress Award; In addition, more than 60 scientific research achievements have been awarded by the state, the Ministry of Health and other departments. With the development of modern biotechnology, while giving full play to the advantages of traditional biotechnology, the institute will focus on the development of genetic engineering, cell engineering, molecular biology and other fields, and build an important development base for modern biotechnology products in China.

The Institute maintains close contact with many domestic and foreign research institutions, laboratories and the World Health Organization. Some famous international scholars and officials of the World Health Organization have visited the hospital many times, with 600 person-times since 1978. The scientific and technical personnel and experts of the institute are sent abroad for further study, investigation or attending international conferences. Chen Zhengren, Zhang Yihao, Su Wannian and other experts of the Institute have successively served as members of the Global Expanded Programme on Immunization Advisory Group. Chengdu Institute of Biological Products is one of the largest research and production bases of biological products in China, covering an area of more than 480,000 square meters. It belongs to China Biotechnology Group, an important state-owned enterprise managed by SASAC the State Council. Since the establishment of 1958, Chengdu Institute, as the planned immunization cooperation center of six provinces, municipalities and autonomous regions in southwest China, has been committed to the research of medical microbiology, immunology, cell engineering and genetic engineering for a long time, producing and selling biological products such as preventive products, blood products, diagnostic products and genetic engineering products.

"Rong Sheng" brand products mainly cover five categories: first, blood products, such as human albumin, Rong Sheng refined ice, Rong Sheng Puyi and so on; The second is bacterial vaccine and toxoid, such as BCG, DTP and live Japanese encephalitis vaccine. The third is immunomodulation, such as Shu Ning; Fourth, diagnostic supplies, such as salmonella diagnostic serum and syphilis diagnostic preparations; Fifth, genetic engineering products, such as granulocyte colony stimulating factor and genetically engineered hepatitis B vaccine. All production workshops have passed the national GMP certification.

Jieyiwei (live attenuated Japanese encephalitis vaccine) produced in Chengdu has protected more than 300 million children in China from Japanese encephalitis. The excellent quality of this new vaccine and its successful clinical application have attracted great attention in the field of vaccine all over the world. 1997, the product was registered overseas and entered the international market in 2002. In 2006, it was exported to India. Many countries expressed the hope that Chengdu Institute would become the main supplier of vaccine products.

Chengdu Rong Sheng Pharmaceutical Co., Ltd., which is controlled by Chengdu, specializes in the research, development, production and management of blood products, and has created and maintained a number of "firsts" in the domestic blood products industry, and has always been in the leading position in the industry. "Rong Sheng" brand blood products have been praised as "the model of blood products" by the Ministry of Health and won wide acclaim in the market.

Chengdu has a strong technical force, a large number of old experts and scholars with profound academic attainments, and young scientific and technological personnel who are in their prime of life and master modern technology, and has built a strong talent cluster. Chengdu Institute has more than 800 employees, including nearly 130 scientific and technical personnel, more than 200 middle and senior technical personnel, and 27 experts enjoying government subsidies.

Chengdu Rong Sheng Pharmaceutical Co., Ltd.

Chengdu Rong Sheng Pharmaceutical Co., Ltd. was established in March 2007 1997. It is a high-tech biopharmaceutical enterprise integrating research and development, production and management of blood products. Is one of the largest manufacturers of blood products in China, and its controlling shareholder is Chengdu Institute of Biological Products of China Biotechnology Group. The registered capital is 8326 1 10,000 yuan, the total assets are nearly 600 million yuan and the annual sales are nearly 300 million yuan. The company has been awarded the honor of "abiding by contracts and valuing credit", "key advantage enterprise in Chengdu" and "top ten enterprises in high-tech zone" by the government for years. At present, the usage of "Rong Sheng human albumin" has exceeded180,000 person-times, and the usage of "Rong Sheng refined ice" has exceeded 4 million person-times. Clinical practice has fully proved their safety and effectiveness. "Rong Sheng" brand blood products are guaranteed by strict management measures in terms of quality and quality control, and are praised as "the model of blood products" by the Ministry of Health, which has won extensive praise from doctors and patients.

Chengdu Institute of Biological Products, the controlling shareholder of the company, is one of the six domestic biological products research institutes, which was established in 1953. It is an important institution engaged in the research and development of medical microbiology, immunology, cell engineering and genetic engineering in China. It is also the earliest enterprise to start large-scale industrial production of blood products in China and one of the largest production bases of blood products in China. With the comprehensive advantages of scale, quality, safety and brand, Rong Sheng brand blood products produced by Rong Sheng brand occupy an undisputed leading position in China blood products market and win a high market reputation. From 65438 to 0996, Rong Sheng albumin successfully passed the testing of WHO recommended standards and USP standards, and was exported to North American countries for the first time, which achieved a breakthrough in the export of blood products in China. Wuhan Institute of Biological Products was established in 1950, formerly directly under the Ministry of Health, and now under the China Biotechnology Group. It is the main research institution of national medical microbiology, immunology, cell engineering and genetic engineering, and a large-scale high-tech enterprise that produces biological products for human use. It is the first batch of doctoral and master's degree awarding points in China, and it is also the planned immunization guidance center in Central and South China and one of the six major biological products production bases in China.

The Institute has made great progress in the production and scientific research of biological products, and trained a large number of experienced biological products experts, including WHO experts 1 person, National New Drug Evaluation Committee experts 12 person, 4 members of the Biological Products Standardization Committee of the Ministry of Health, and 23 people who enjoy subsidies from the state, provinces and municipalities. He has successively undertaken a number of major projects such as national key research plan, "863" plan, "863" youth research fund, national natural science fund, national science and technology support plan, torch plan, spark plan, provincial and municipal key research plans, etc., and won achievement awards at all levels and scientific and technological progress award 138. With cell engineering, genetic engineering, biological fermentation, monoclonal antibodies, protein purification and many other high-tech products. The establishment of P3 laboratory further strengthened the research strength of Wuhan Institute of Biological Products.

In addition to completing the scientific research and production task of national compulsory preventive biological products, the institute is also committed to the research and development of high-tech drugs, especially in four series of blood products, new therapeutic products and diagnostic reagents, producing more than 30 products with specifications of 100. The product quality of Wuhan Institute of Biological Products is stable, and the quality assurance system runs through the whole process from raw material procurement to finished products and product sales. The quality of many major products has always maintained the national leading level, and more than ten products have won national, provincial and municipal quality product awards, which have achieved good economic and social benefits and made great contributions to the prevention and treatment of diseases and the protection of people's health in China.

Since 1978 resumed postgraduate education, Wuhan Institute of Biological Products is the first batch of doctoral and master's degree awarding units in microbiology and immunology approved by the State Council, and it is also the only doctoral program in the national biological products system. In the early 1990 s, according to the provisions of the State Education Commission, it was changed to: immunology majors have the right to award doctoral and master's degrees; The specialty of pathogenic biology has the right to grant master's degree. In the training of graduate students, we insist on the combination of scientific and technological innovation and personnel training, and constantly expand the enrollment scale. At present, there are more than 40 students. Postgraduates' professional basic education is carried out in Tongji Medical College of Huazhong University of Science and Technology, and the research topic is completed in the institute of tutor work. Changchun Institute of Biological Products was founded in 1934, then called "Institute of Health and Welfare". 1946 was accepted by the Northeast Anti-Japanese Democratic Coalition Forces. It is a large state-owned pharmaceutical biotechnology enterprise integrating science and technology, development, production and marketing. It is an important production and research base of biological products and high-tech products for prevention, treatment and diagnosis, and also a research center of microbiology and immunology in Northeast China. At the beginning of 1999, during the great changes in the adjustment and reform of various ministries and commissions in the State Council, the Institute was decoupled from the Ministry of Health and is now managed by China Biotechnology Group Company. * * * There are seven production workshops, and 43 varieties have passed the national GMP certification and obtained the GMP certificate issued by the US Food and Drug Administration.

Changchun has a strong technical force, and a large number of experts and scholars with profound academic attainments have led and trained a group of high-level, high-quality, innovative and compound talents who actively study biopharmaceutical technology. At present, there are 94 senior professional titles, 389 intermediate professional titles and 279 junior professional titles, and college degree or above accounts for more than 62%. 1992 was approved by the State Council Academic Degrees Committee as a master's degree awarding unit, with two professional authorization points of "medical immunology" and "pathogenic biology", and so far more than 0/00 graduate students have been trained. 200 1 was approved as "postdoctoral research center" by the Ministry of personnel.

Changchun Institute is a national key biopharmaceutical enterprise, and has successively undertaken major scientific and technological projects such as the Seventh Five-Year Plan, the Eighth Five-Year Plan, the Ninth Five-Year Plan, the National High-tech Research and Development Plan (863 Plan), the Torch Plan, the New Drug Research Fund Plan, the Tenth Five-Year Plan, the Innovation Fund Plan of the Ministry of Science and Technology, the high-tech industrialization project to revitalize the old industrial base in Northeast China, and the provincial (city) level scientific and technological development plan. Won the National Technological Invention Award 1 item, the National Science and Technology Progress Award 12, the National Science and Technology Conference Award 17, 46 national ministries awards, 76 national awards, and 9 provincial awards such as the Provincial Science and Technology Progress Award1item. National invention patents 19 have been applied, of which 5 were authorized; 2 design patents; 4 international invention patents.

Changchun is rich in intangible assets, with 60 production approval documents, and has the unique advantage of diversified product structure in the biological products industry. Changchun Institute of Traditional Chinese Medicine is the first interferon pilot base in China; The first industrialized production base of hepatitis B genetic engineering vaccine; The first enterprise to obtain the production number of recombinant human interleukin-2.

The hepatitis A vaccine developed and produced by Changchun Institute is a high-tech biological product with independent intellectual property rights and won the second prize of national scientific and technological progress. The hepatitis B gene vaccine is a new kind of national biological products. It is the first manufacturer in China to obtain the official production number of hepatitis B genetic engineering vaccine, and has won the national new product award and the first prize of national scientific and technological progress twice.

The main products of Changchun Research Institute are biological products, diagnostic products and genetic engineering products, including vaccines, bacterin, toxoid, antitoxin, immune serum, blood products, cytokines, monoclonal antibodies, immunodiagnostic reagents and other types. The main products are freeze-dried live attenuated hepatitis A vaccine, split influenza vaccine, purified rabies vaccine for human use, recombinant (CHO cell) hepatitis B vaccine, epidemic hemorrhagic fever vaccine, purified forest encephalitis vaccine, anti-rabies serum and other products.

Changchun Qijian biology products co., ltd

Changchun Qijian Biological Products Co., Ltd. (referred to as "Qijian Biological Products") successfully realized the equity reorganization in September 2006. After the reorganization, Beijing Tiantan Biological Products Co., Ltd., Changchun Biological Products Research Institute and China Scientific Equipment Import and Export Corporation held 5 1%, 39% and 10% shares respectively. Through the joint efforts of all shareholders and employees of Qijian Bio, the corporate governance structure of the company has been further optimized. The company adheres to the principle of "everything starts with communication and everything starts with seriousness", pays attention to quality and image, and pays attention to cooperation with the national disease control system.

The freeze-dried live attenuated varicella vaccine produced by Qijian Bio has been on the market for ten years. In 2008, the usage of the company's products in China reached a record high, and they were exported to South Korea, India and other countries. Qijian Bio is building a new factory, which will expand the production scale of varicella vaccine and resume the production of original measles vaccine. Lanzhou Institute of Biological Products was established in 1934. Its predecessor is the former National Northwest Epidemic Prevention Department, and it is one of the oldest biological products research institutes in China. 1953 moved to the current address (No.888 Yanchang Road, Chengguan District, Lanzhou City), which was originally under the management of the Ministry of Health. 1985, transformed from a public institution into an enterprise. 1999, which is under the management of the Central Enterprise Working Committee of the former State Economic and Trade Commission. Since 2002, it has been managed by the State Council State-owned Assets Management Committee, and it is a secondary subsidiary of China Biotechnology Group Corporation. In September 2009, China Pharmaceutical Group Co., Ltd. and China Biotechnology Group Co., Ltd. were jointly reorganized, and became the second-class enterprise of China Pharmaceutical Group Co., Ltd.

Lanzhou Institute of Biological Products is mainly engaged in the production, research and development and management of biological products. It is the backbone enterprise of the national biological products industry and the only large-scale biological high-tech enterprise in our province and even in the northwest. It is an important research institution of national medical microbiology, immunology and molecular biology; National Science and Technology "863" Plan Industrialization Base; Enterprise technology center recognized by the state and Gansu enterprise technology center; The postdoctoral workstation established by the Ministry of Personnel has the right to confer master's degrees approved by the the State Council Academic Degrees Committee; Ministry of Civil Affairs "Tomorrow Plan" designated supplier of medical rehabilitation drugs. National Training Base of China Institute for the Control of Pharmaceutical and Biological Products, US Food and Drug Administration. National state-owned enterprises set up "four good" leading bodies and advanced collectives. In April 2009, he was awarded the "National May 1 Labor Award" by the All-China Federation of Trade Unions.

Lanzhou Institute of Biological Products covers an area of 430,000 square meters with total assets of 654.38+373 million yuan. In 2008, the sales revenue was 797 million yuan and the profit was 365.438+200 million yuan. Asset scale, sales revenue and realized profits and taxes all rank first in the biomedical industry in our province. Employees 1400, including more than 650 technicians, accounting for 46% of the total number of employees in the hospital; There are more than 800 people with technical secondary school education, accounting for 57% of the total number of people in the institute, and the profit ranks 17 in the national pharmaceutical industry.

Lanzhou Institute of Biological Products has established a perfect quality assurance system, and all workshops have passed the GMP certification organized by SFDA. Every year, nearly 654.38 billion doses of various vaccines (blood products) are produced, and the products are sold to all provinces, municipalities and autonomous regions except Taiwan Province Province, which provides a solid guarantee for the health of people of all ethnic groups in China.

Lanzhou Institute of Biological Products has six professional laboratories, two state-level strain preservation centers and a biosafety laboratory. Have a reasonable echelon, excellent quality, dedication and enterprising young and middle-aged scientific and technological team, as well as academic leaders with certain influence in the same industry in China. There are more than 120 scientific and technical personnel engaged in biotechnology research and development, including 1 1 person. After more than 70 years of efforts, scientific research and development have laid a good foundation and formed unique scientific research topics and research directions. Lanzhou Institute of Biological Products has a good cooperative relationship with many famous research institutions at home and abroad.

Lanzhou Institute of Biological Products won nearly 100 scientific and technological awards at or above the provincial level. In the past ten years, we have obtained four varieties of national first-class new drugs, eight varieties of second-class new drugs, two varieties of third-class new drugs, and four kinds of new drugs and generic drugs 13 varieties. Won the first prize of national scientific and technological progress 1, 4 second prizes, 2 DuPont scientific and technological innovation prizes and 8 provincial and ministerial scientific and technological progress. The industrialization of these scientific research achievements not only produced good economic benefits, but also effectively improved the level of biotechnology industry in our province and Lanzhou city.

Botulinum toxin A independently developed by Lanzhou Institute of Biological Products won the second prize of National Science and Technology Progress Award. It is the exclusive biological product approved for production and sales in China, and the first biological product exported independently in China. At present, it has registered in more than 20 countries and enjoys a good reputation in the international market. Haemophilus influenzae type B conjugate vaccine and oral rotavirus live vaccine are exclusively produced in China. The bivalent vaccines of meningococcal polysaccharide produced by group A and group C account for more than 80% of the national market and have been successfully sold to Africa. The output of live attenuated measles vaccine accounts for more than 70% of the national market, which plays an important role in achieving the goal of eliminating measles proposed by the Ministry of Health. The sales revenue of new products with independent intellectual property rights accounts for more than 80% of the total sales revenue. Established in 1949, Shanghai Institute of Biological Products is a large state-owned high-tech enterprise integrating research, development, production and management of biological products. It is a national master's degree awarding unit in biochemistry, molecular biology and pathogenic biology, the first batch of enterprises granted the right to import and export, and one of the important bases for scientific research and production of biological products in China.

Shanghai Institute of Biological Products has more than 300 employees 1, including more than 300 professional technicians 1, including more than 300 senior and intermediate technical titles, 7 graduate tutors, 4 experts enjoying special national allowance 1, 4 members of National Biological Products Standardization Committee, 4 experts in national drug evaluation, and experts from WHO Biological Standardization Advisory Group/kloc-0. The Institute has nine laboratories, including molecular biology and monoclonal technology, genetic engineering protein genomics, bacterial polysaccharide, molecular virus, plasma protein and its preparation, biotechnology information and epidemiology, diagnostic reagents and microecology, biotechnology and comprehensive research on experimental animals, which are devoted to the research and development of new products. He has successively completed dozens of national scientific research tasks, such as the Seventh Five-Year Plan, the Eighth Five-Year Plan and the 863 key projects. More than one scientific research achievement 100 has been obtained, of which more than 30 have won the state science and technology commission, the Ministry of Health or the Shanghai Science and Technology Progress Award. At the end of 1980s, interferon α 1b, which was jointly developed with Institute of Virology of Preparatory Institute, was the first industrialized therapeutic genetic engineering product in China, a national first-class drug, and won the first prize of national scientific and technological progress. Interferon γ developed later won the second prize of National Science and Technology Progress Award.

Shanghai Biological Products Research Institute has more than 200 production documents approved by all countries, including blood products, preventive products, genetic engineering products and various diagnostic reagents. It has a large-scale blood preparation production line with advanced equipment and a vaccine production building that meets European GMP standards. All the workshops have passed the national GMP certification, and the output value in 2005 exceeded 654.38+0 billion yuan. 1996 and 2000 successively imported high-tech products such as chicken pox vaccine and influenza vaccine from Japan, and the production scale was continuously expanded, and the quality reached the international advanced level, and won the title of "Shanghai Top 100 High-tech Achievements Transformation Project". Chickenpox, influenza, measles, mumps, human albumin and other products were awarded as "key new products" in China and Shanghai respectively, and "famous products" in Shanghai pharmaceutical industry. We have established a nationwide sales network centered on East China to provide customers with perfect technical support and after-sales service. Our brand Shangsheng enjoys a high reputation in China. China Gu Wei Biomedical Co., Ltd., located in Beijing, is a new scientific research enterprise integrating scientific research and production, which is jointly funded by China Biotechnology Group, Beijing Tiantan Biological Products Co., Ltd., Beijing Institute of Biological Products and China Center for Disease Control and Prevention (CDC).

Beijing Gu Wei Biomedical Co., Ltd. undertook the construction of the national key project "National Engineering Research Center for New Vaccines". National Vaccine Center is the only national new vaccine research and development and industrialization base and service platform approved by the National Development and Reform Commission to implement the major strategic decision of the CPC Central Committee and the State Council on building an innovative country. The construction site is located in Beijing Economic and Technological Development Zone, with a planned construction area of 23,000 square meters and a total investment of 2 1 10,000 yuan. The foundation stone was laid on June 29th, 2009, and it is planned to be fully completed on February 20th10.

As a national technology research and development and engineering technology transformation platform, the facilities of the National Vaccine Center are built according to GMP, GLP and biosafety standards of China, the European Union and the United States, and a number of international advanced technologies and processes are concentrated, which can undertake engineering research and development and technical support for major national and local projects. The National Vaccine Center will build five pilot production units (including three BSL-2 areas with biosafety level II) that meet EU GMP standards, including live vaccine and inactivated vaccine production units, bacterial vaccine production units, genetic engineering production units and insect cell production units; 4 professional laboratories (including 2 BSL-2 laboratories with biosafety level II), including virus laboratory, bacteria laboratory, genetic engineering laboratory and QC laboratory; Two sub-packaging units (live and inactivated seedlings), packaging area, laboratory animal room and other supporting facilities.

The main goal of Beijing Gu Wei Biomedical Co., Ltd. is to apply modern biotechnology to transform traditional vaccines, solve major technical problems in the research and development and industrialization of new vaccines, focus on the research and development, pilot production and biotechnology consulting services of new vaccines, recombinant proteins, polypeptide drugs, nucleic acid drugs and diagnostic reagents, and provide a complete engineering and industrialization technology platform for the research and development of new vaccines in China and mature advanced production technologies. The development direction of scientific research is to apply modern biotechnology to improve traditional vaccines, overcome technical problems in the research and development and industrialization of new vaccines, provide a complete engineering and industrialization technology platform for the research and development of new vaccines, and provide mature and advanced production processes and technologies. The work focuses on the research and development and pilot production of new vaccines, recombinant proteins, polypeptide drugs, nucleic acid drugs, diagnostic reagents and other biomedicine, and provides related biotechnology consulting services.

The National Vaccine Center has been included in the national high-tech industry development project plan and the national fund subsidy plan, and joined the China Biotechnology Innovation Service Alliance (ABO). At the same time, it undertakes the "863" project plan of the Ministry of Science and Technology, major infectious diseases projects, supporting projects, international scientific and technological cooperation projects, major projects in Beijing, etc. 10. In addition, the National Vaccine Center has also carried out extensive exchanges and cooperation with many units at home and abroad, and reached more than 10 cooperation projects.